Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Hepatobiliary Diseases

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1679733

Progression characteristics of Biliary Atresia during the Waiting Period for Liver Transplantation: A Single-Center Observational Study

Provisionally accepted
Chenyu  YangChenyu Yang1,2Jiqiang  HuJiqiang Hu1,2Bingqian  TanBingqian Tan1,2Qiang  XiongQiang Xiong1,2Ruijue  WangRuijue Wang1,2Jianyang  HuJianyang Hu1,2Ying  LeYing Le1,2Xiaoke  DaiXiaoke Dai1,2*Mingman  ZhangMingman Zhang1,2*
  • 1Children‘s Hospital of Chongqing Medical University, Chongqing, China
  • 2Chongqing Medical University, Chongqing, China

The final, formatted version of the article will be published soon.

Background Biliary atresia (BA) is a progressive, fibro-obliterative cholangiopathy of infancy that inevitably leads to cirrhosis and liver failure without intervention. While the rapid progression of BA is widely recognized, the precise dynamics of its natural history remain poorly quantified due to the confounding effects of surgical intervention. Aims This study aimed to characterize the natural progression of BA cirrhosis by analyzing the trajectory of clinical, laboratory, and histological changes during the unique window between diagnostic confirmation by intraoperative cholangiography and subsequent liver transplantation in children who did not undergo Kasai portoenterostomy. Methods In this single-center, observational study, we analyzed 153 children with cholangiography-confirmed BA who underwent living donor LT without primary Kasai portoenterostomy. The pathological progression of cholestatic cirrhosis and laboratory parameters such as hematological examination and liver function in children with hepatic cholestatic cirrhosis at the two time points were compared to find factors that can predict the progression of BA cirrhosis. Results The cohort comprised 153 children with cholangiography-confirmed BA who underwent liver transplantation. The mean age at diagnosing BA was 78.64 ± 31.43 days. The mean interval from exploration to liver transplantation (disease progression time) was 83.36 ± 28.37 days. Within this short period, 77.12% (118/153) of children progressed to end-stage (Stage IV) cirrhosis. Longitudinal analysis revealed a significant increase in white blood cells (WBC, 3.09±5.31×10⁹/L), neutrophil percentage (NE%, 7.42±13.77%), total bilirubin (TBIL, 121.9 ± 99.51 μmol/L), and serum ammonia (SA, 6.97±25.59 μmol/L), alongside a significant decrease in hemoglobin (HB; -4.7±15.83 g/L), platelets (PLT; -148.50±154.40× 10⁹/L), and albumin (ALB; -4.60±7.28 g/L) (all p < 0.05). A predictive model incorporating initial fibrosis stage, waiting time, and changes in NE% and SA demonstrated good accuracy (75.96% in training set, 72.00% in validation set) for forecasting cirrhosis progression. Conclusion This study provides unprecedented quantification of the rapid natural progression of BA cirrhosis, revealing a critical 3 month window of clinical deterioration. The dynamic changes in routinely available laboratory markers, particularly neutrophil percentage and ammonia, offer clinically accessible indicators for risk stratification and monitoring, forming a practical "dashboard" for managing BA patients awaiting transplantation in resource-varied settings.

Keywords: Biliary Atresia, Intraoperative cholangiogram, Liver Cirrhosis, Natural progression, Kasai portoenterostomy (KPE)

Received: 05 Aug 2025; Accepted: 08 Oct 2025.

Copyright: © 2025 Yang, Hu, Tan, Xiong, Wang, Hu, Le, Dai and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiaoke Dai, xiaokedai2022@163.com
Mingman Zhang, zhangmingman-a@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.